Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Natera Announces Surveillance Analysis From Phase 3 IMvigor011 Trial in Muscle-Invasive Bladder Cancer, Data Shows Patients Who Remain Signatera MRD-negative After Surgery May Be Spared From Adjuvant Treatment, With 100% Overall Survival At 12 Months

Author: Benzinga Newsdesk | April 05, 2024 07:04am
  • Overall survival (OS) rates of 100% at 12 months and 98% at 18 months, in patients who remained serially MRD-negative.
  • Disease-free survival (DFS) rates of 92% at 12 months and 88% at 18 months, in patients who remained serially MRD-negative.
  • Concludes that patients who remain MRD-negative on serial testing may be spared from adjuvant treatment.

Posted In: NTRA


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist